“…Although Eli Lilly and Shionogi developed a series of very potent sPLA 2 inhibitors, such as LY-311727 (10), LY-315920 (14) and indoxam (15), no inhibition data have been presented with the classical anti-inflammatory in vivo test systems such as the carrageenan-induced paw oedema model of the rat, the adjuvant-induced arthritis model of the rat and the phorbolester (TPA)-induced mouse ear oedema assay [5,6,72]. Boehringer Mannheim (now Roche Diagnostics) could only achieve inhibition of the carrageenan oedema with their sPLA 2 -IIA inhibitors, while these compounds were totally inactive in the chronic adjuvant arthritis model [63]. Glaxo Wellcome (now GlaxoSmithKline) decided to abandon sPLA 2 as a molecular target for development of anti-inflammatory drugs since sPLA 2 inhibitors developed by this company had only modest activities in the carrageenan oedema model, even after optimisation of the pharmacokinetic parameters and the metabolic stability of the compounds [67].…”